On January 10, SciWind Bio announced a global development and commercialization license and collaboration agreement with Verdiva Bio, excluding Greater China and South Korea. Verdiva Bio is a clinical – stage global biopharmaceutical company focused on developing innovative therapies for obesity and other cardiovascular metabolic disorders.
Collaboration Details
The collaboration includes a pipeline of products:
- Oral Ecnoglutide (XW004) : A once – weekly oral GLP – 1 receptor agonist preparing for Phase II clinical trials.
- Oral Amylin Receptor Agonist (Amylin RA) : A once – weekly oral amylin receptor agonist in preclinical development, designed for monotherapy or combination with GLP – 1 receptor agonists.
- Subcutaneous Amylin Receptor Agonist (Amylin RA) : A long – acting subcutaneous amylin receptor agonist in preclinical development, also intended for monotherapy or combination with GLP – 1 receptor agonists.
Agreement Terms
Under the agreement, SciWind Bio grants Verdiva Bio exclusive rights to develop, produce, and commercialize the above product portfolio globally, excluding Greater China and South Korea. SciWind Bio retains rights in other regions. SciWind Bio will receive nearly USD 70 million in upfront payments and is eligible for up to USD 2.4 billion in potential development, regulatory, and commercialization milestone payments, as well as tiered royalties on product sales. The companies will also collaborate on other preclinical projects, with SciWind Bio entitled to corresponding milestone payments and royalties.
Verdiva Bio Background
Verdiva Bio, founded by industry experts and serial entrepreneurs, has extensive experience in the global treatment of metabolic diseases. The company plans to advance the development of these new products through a series of clinical research programs involving monotherapy and combination therapies.-Fineline Info & Tech
